Details for New Drug Application (NDA): 211510
✉ Email this page to a colleague
The generic ingredient in LIOTHYRONINE SODIUM is liothyronine sodium. There are four drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the liothyronine sodium profile page.
Summary for 211510
Tradename: | LIOTHYRONINE SODIUM |
Applicant: | Teva Pharms Usa |
Ingredient: | liothyronine sodium |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Suppliers and Packaging for NDA: 211510
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LIOTHYRONINE SODIUM | liothyronine sodium | TABLET;ORAL | 211510 | ANDA | Teva Pharmaceuticals USA, Inc. | 0093-2178 | 0093-2178-01 | 100 TABLET in 1 BOTTLE (0093-2178-01) |
LIOTHYRONINE SODIUM | liothyronine sodium | TABLET;ORAL | 211510 | ANDA | Teva Pharmaceuticals USA, Inc. | 0093-2179 | 0093-2179-01 | 100 TABLET in 1 BOTTLE (0093-2179-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 0.005MG BASE | ||||
Approval Date: | Oct 26, 2018 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 0.025MG BASE | ||||
Approval Date: | Oct 26, 2018 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 0.05MG BASE | ||||
Approval Date: | Oct 26, 2018 | TE: | AB | RLD: | No |
Complete Access Available with Subscription